A First in Human Study to Assess Safety, Tolerability and Pharmacokinetics of a Single Dose of REGN22044 in Healthy Adults

NCT07526116 · clinicaltrials.gov ↗

PHASE1

Phase

NOT_YET_RECRUITING

Status

64

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy Volunteer

Interventions

DRUG: REGN22044
DRUG: Placebo

Sponsor

Regeneron Pharmaceuticals